Percheron Therapeutics

Default features description for sign up page.

HOME

INVESTORS

PATIENTS

WHY INVEST

UPDATES

RESEARCH REPORTS

PRESENTATIONS

SHARE PRICE

ASX ANNOUNCEMENTS

ANNUAL REPORTS

PARTNERSHIPS & COLLABORATORS

CORPORATE GOVERNANCE

CORPORATE DIRECTORY

MEET THE TEAM

ABOUT

HMBD-002

PIPELINE

Titillium Web

Percheron Therapeutics (ASX: PER) has just received a major scientific boost, with new preclinical data showing that its antibody therapy, HMBD-002, significantly enhances the effects of radiotherapy in treating head and neck cancer.

The study, led by Stanford University, used advanced patient-derived models — essentially implanting human tumours into mice — to replicate real-world cancer biology. When HMBD-002 was combined with radiotherapy, researchers saw powerful tumour suppression and a notable improvement in survival outcomes.

HMBD-002 works by targeting VISTA, an immune checkpoint linked to treatment resistance. And while animal studies don’t always mirror human responses, this research strongly supports moving forward with clinical trials — especially in tough-to-treat cancers like squamous cell carcinoma, lung, breast, and melanoma.

Percheron's CEO, Dr James Garner said: "The Stanford team, under Professor Le’s oversight, are comprised of leading experts in this field, and we look forward to discussing the work further with them in due course."

Percheron Therapeutics' antibody shows promise in enhancing radiotherapy for head and neck cancer

Proactive Interview 🎥 | Percheron Therapeutics' antibody shows promise in enhancing radiotherapy for head and neck cancer